SCHEMBL2321113

SCHEMBL2321113

C=CCC(NC(=O)O)c1ccccc1Br

nearest known ligand 0.43

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
CYP26A1 O43174 3/20 0.43
HTT P42858 1/20 0.42
CYP2C19 P33261 3/20 0.41
SMN1; SMN2 Q16637 1/20 0.39
CYP2C9 P11712 1/20 0.37
TDP1 Q9NUW8 1/20 0.36
ALDH1A1 P00352 3/20 0.35
KDM4E B2RXH2 1/20 0.35
MAPT P10636 1/20 0.35
ALOX15 P16050 1/20 0.35
HSD17B10 Q99714 1/20 0.35
TSHR P16473 1/20 0.35
ATM Q13315 1/20 0.35
L3MBTL1 Q9Y468 1/20 0.35
MMP2 P08253 4/20 0.34
MMP3 P08254 4/20 0.34
MMP7 P09237 3/20 0.34
MMP1 P03956 3/20 0.33
MMP8 P22894 2/20 0.33
HPGD P15428 1/20 0.33

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL2331441 0.80 MAPT (0.45) HTTCYP2C19SMN1; SMN2CYP2C9ALDH1A1
SCHEMBL2331444 0.80 MAPT (0.45) HTTCYP2C19SMN1; SMN2CYP2C9ALDH1A1
SCHEMBL2899494 0.79 CYP2C19 (0.56) HTTCYP2C19SMN1; SMN2ALDH1A1KDM4E
SCHEMBL31146140 0.76 SMN1; SMN2 (0.41) CYP26A1HTTCYP2C19SMN1; SMN2CYP2C9
SCHEMBL2359345 0.76 CYP26A1 (0.46) CYP26A1HTTCYP2C19SMN1; SMN2CYP2C9
SCHEMBL2320758 0.75 SMN1; SMN2 (0.46) CYP26A1CYP2C19SMN1; SMN2TDP1ALDH1A1
SCHEMBL2320767 0.75 SMN1; SMN2 (0.46) CYP26A1CYP2C19SMN1; SMN2TDP1ALDH1A1
SCHEMBL18425130 0.74 ALDH1A1 (0.43) CYP26A1HTTCYP2C19SMN1; SMN2ALDH1A1
SCHEMBL16972136 0.74 ALDH1A1 (0.43) CYP26A1HTTCYP2C19SMN1; SMN2ALDH1A1
SCHEMBL614703 0.73 MMP1 (0.38) MMP3MMP7MMP1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2356105-B1 ( PYRROLIDIN-2 -YL) PHENYL DERIVATIVES FOR USE IN THE TREATMENT OF PAIN MSD OSS BV (NL) 2013-04-10 EP disclosed
US-8188123-B2 (Pyrrolidin-2-yl)phenyl derivatives MERCK SHARP & DOHME B.V. (NL) 2012-05-29 US disclosed
EP-2356105-A1 ( PYRROLIDIN-2 -YL) PHENYL DERIVATIVES FOR USE IN THE TREATMENT OF PAIN N.V. Organon (NL) 2011-08-17 EP disclosed
WO-2010052198-A1 ( PYRROLIDIN-2 -YL) PHENYL DERIVATIVES FOR USE IN THE TREATMENT OF PAIN N.V. ORGANON (NL) 2010-05-14 WO disclosed
US-20100113493-A1 (PYRROLIDIN-2-YL)PHENYL DERIVATIVES N.V. ORGANON 2010-05-06 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20100113493-A1 (PYRROLIDIN-2-YL)PHENYL DERIVATIVES CNR1, CNR2, TRPV1 CYP26A1 2454/4885HTT 123/4885CYP2C19 772/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.